HOYA Group’s PENTAX Medical and Jiangsu Vedkang Medical Science and Technology have formed a joint venture (JV) to create single-use, flexible medical endoscopic therapeutic products.
The JV, named PENTAX Medical Therapeutics (Jiangsu), will leverage PENTAX’s marketing network to provide advanced single-use devices to clients globally. The offering will be reinforced by Vedkang’s production and research and development framework.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataMedical flexible endoscopes and therapeutic devices are utilised in less-invasive procedures.
The devices could benefit patients, physicians and medical care systems by reducing the cost or complexity of procedures. This could also result in improved recovery time for patients.
PENTAX Medical global president Gerald Bottero said: “Our collaboration will support the fast-growing Endotherapy segment as new and innovative procedures achieve traction and penetration worldwide.
“Now PENTAX Medical, together with Vedkang, looks forward to offering integrated endoscopy solutions to our valued global customers.”
To be headquartered in China, PENTAX Medical Therapeutics intends to develop and market products for major markets in Europe, Asia and the Americas.
Jiangsu Vedkang Medical Science and Technology chairman and CEO Zhuang XiaoJing said: “PENTAX Medical has always been a valuable business partner to Vedkang, and we are delighted to continue our close relationship in this JV by pursuing further possibilities with doctors and patients across the world.”
Last month, PENTAX Medical Europe received CE mark for its latest single-use bronchoscope, PulmoONE, which offers high-quality care without risking the level of pulmonary care.
The working channel of PulmoONE offers up to 50% increased suction power for rapid and effective patient care. It also delivers greater sterility along with high definition (HD) visualisation, thereby widening its clinical uses beyond the traditional disposable scope, the company said.
